A sequence is a design. Getting from that design to a vial of characterized material takes one three-step cycle, repeated once per amino acid — and a great deal of care about what happens when it doesn’t work perfectly.
A peptide is, on paper, a simple object: a defined sequence of amino acids joined end to end. Writing one down takes seconds. Building one is considerably harder.
The difficulty is not forming a peptide bond. Chemists have been doing that since Emil Fischer and Ernest Fourneau assembled glycylglycine — the first free dipeptide — in 1901; Fischer supplied the field’s vocabulary a year later. The difficulty is forming exactly the bonds you intend, in exactly the order you intend, dozens of times in succession — while every amino acid in the flask carries additional reactive groups that would be perfectly happy to react instead. And then demonstrating, afterward, that the molecule you isolated is the molecule you designed.
The dominant solution to that problem is a technique called solid-phase peptide synthesis (SPPS), introduced by R. Bruce Merrifield in 1963 and recognized with the Nobel Prize in Chemistry in 1984.[1] It is one of those rare methods that changed a field not by making an existing process faster, but by reorganizing it around a single structural insight.
This article walks through that insight and its consequences: how a sequence becomes a resin-bound chain, how that chain becomes a crude mixture, and how that mixture becomes characterized research material. Before going further, it may help to review what peptides are and how their structure relates to their behaviour — this article picks up where that one ends.
What Is Peptide Synthesis?
Peptide synthesis is the controlled chemical construction of a peptide with a predetermined amino acid sequence.
Peptides can also be obtained biologically — extracted from tissue, or produced by engineered bacteria or yeast that transcribe and translate an inserted gene. Both routes remain important, and several commercially significant peptides are made recombinantly or by hybrid routes that combine biological expression with downstream chemical modification. But chemical synthesis offers something biology does not: complete freedom over the sequence.
That freedom matters for research. A ribosome builds from a fixed set of twenty proteinogenic amino acids, all L-configured apart from achiral glycine. A synthetic chemist is not constrained that way. D-amino acids, N-methylated residues, unnatural side chains, fluorophores, isotopic labels, cyclization handles, lipid conjugates — none of these are available to a standard expression system without considerable engineering, and all of them are routine in synthesis. When a research question requires a systematic series of sequence variants, chemical synthesis is usually the only practical way to produce them.
Scale and speed also favour synthesis for shorter chains. For a peptide of a few dozen residues, chemical assembly is typically faster to set up than establishing an expression system, and it avoids the biological contaminants — host cell proteins, endotoxin, viral or prion risk — that come with living production hosts. Peptide-based drugs, of which more than eighty have been approved worldwide, are manufactured by both routes depending on length, modification and volume.[2]
The chemistry underneath is the same reaction throughout: the amine group of one amino acid attacks the carboxyl group of another to form an amide bond — the peptide bond — in what is formally a condensation releasing water. Everything else is control.
Why Solid-Phase Peptide Synthesis Matters
Before 1963, peptides were built in solution. Each amino acid was added in a flask, and after each addition the growing peptide had to be isolated and purified before the next step could begin. Yields eroded. Handling losses compounded. Assembling a chain of even modest length was a research project in itself.
Merrifield’s reorganization: anchor the growing peptide to an insoluble solid, and purification becomes filtration.
The peptide is covalently attached at one end to a small polymer bead — the resin — that does not dissolve in the reaction solvent. Reagents are added in solution. When the reaction is done, the bead is simply washed. Everything soluble drains away; the peptide, tethered to the bead, stays. There is no isolation step, no crystallization, no chromatography between residues. There is a filter.
Two consequences follow, and they explain most of what SPPS looks like in practice.
First, reagents can be used in large excess. In solution chemistry, excess reagent is a purification problem. Anchored to a bead, excess reagent is just something you rinse off. Chemists can therefore drive each coupling step much closer to completion than they could otherwise afford to — which matters enormously when the same step must be repeated dozens of times.
Second, the whole process can be automated. Add, wait, drain, wash, repeat. That is a machine’s job, and it has been since the mid-1960s. Merrifield and Bernd Gutte demonstrated the endpoint of that logic in 1969 by chemically synthesizing ribonuclease A — 124 residues, with catalytic activity.[3] Modern automated synthesizers run the same cycle with far better chemistry.
What a resin actually is
It is worth correcting a common mental image. The resin is not a flat surface with peptides standing on it like bristles on a brush.
Typical SPPS resins are microscopic beads of cross-linked polymer — classically polystyrene lightly cross-linked with divinylbenzene, and increasingly polyethylene-glycol-based materials for demanding sequences. In a suitable solvent the bead swells, sometimes to several times its dry volume, taking up solvent throughout its interior. The chemistry then happens in a solvated gel phase, throughout the three-dimensional polymer network, not on a two-dimensional exterior. The vast majority of attachment sites are inside the bead.
This is why solvent choice is not incidental. A solvent that fails to swell the resin leaves most of the growing chains physically inaccessible to reagents, regardless of how reactive those reagents are. It is also why the field’s ongoing effort to replace hazardous dipolar aprotic solvents such as DMF and NMP with greener alternatives is genuinely difficult chemistry rather than a simple substitution.[4, 5]
Between the resin and the peptide sits a linker: a short chemical connector chosen deliberately. The linker determines the conditions required to release the peptide at the end, and it determines what the peptide’s C-terminus looks like once released — a free acid, an amide, or something else. Choosing the linker is one of the first decisions in designing a synthesis, because it is effectively a decision about the last step.
The Basic SPPS Process
Two features of this diagram deserve attention before the details.
The chain is built backwards relative to how peptides are written. By convention, peptide sequences are written N-terminus to C-terminus, and ribosomes build them in that direction. SPPS runs the other way: the C-terminal residue is attached to the resin first, and each new amino acid is added at the N-terminal end. This is not arbitrary — it is the direction that minimizes racemization of the residue being activated at each step.
The cycle is the entire method. A 30-residue peptide is not thirty different reactions; it is one three-step cycle executed twenty-nine times. Everything that makes SPPS powerful and everything that makes it fail comes from that repetition.
What Happens During Amino-Acid Coupling?
Coupling is the step that forms the new peptide bond. It is also where the selectivity problem becomes concrete.
Consider what an amino acid actually offers a reaction. Every one has an amine group and a carboxyl group. Many also have reactive side chains: lysine has a second amine, aspartate and glutamate have additional carboxyls, serine and threonine and tyrosine have hydroxyls, cysteine has a thiol. Drop a mixture of unmodified amino acids into a flask with a coupling agent and you will get amide bonds — a great many of them, in essentially every possible arrangement, forming an intractable polymeric mess.
Control is imposed by protecting groups: chemical masks attached to functional groups that must not react, removable later under defined conditions.[6]
In practice, a building block used in SPPS carries at least two layers of protection:
- A temporary group on the α-amine, removed at the start of every cycle to expose the amine for the next coupling.
- Permanent — more precisely, semi-permanent — groups on reactive side chains, which stay in place throughout the entire assembly and come off at the end.
The critical requirement is that these two layers be orthogonal: removable by chemically independent conditions, so that stripping the temporary group leaves the permanent ones untouched. Without orthogonality, every deprotection would partially dismantle the side-chain protection, and branching would begin.
Two protection schemes dominate, and they differ in exactly this respect. The older Boc/benzyl strategy removes the temporary group with acid and the side-chain groups with stronger acid — a graduated difference in acid lability rather than orthogonality in the strict sense, which is why it depends on careful control of conditions. The now-standard Fmoc/tBu strategy is built on the base-labile 9-fluorenylmethoxycarbonyl group, which Carpino and Han introduced in 1970 and described in full two years later.[7] It uses a mild base for the temporary deprotection and acid for the final cleavage. Fmoc chemistry’s dominance is largely a matter of those two conditions being genuinely independent — base versus acid — which is orthogonality in the strict sense.
The coupling reaction itself requires activating the incoming amino acid’s carboxyl group, since a plain carboxylic acid is not reactive enough toward an amine under mild conditions. Activation converts it into a species that the resin-bound amine will attack readily. Whole families of reagents exist for this — carbodiimides, uronium and aminium salts, phosphonium reagents, each usually paired with an additive that improves efficiency and suppresses side reactions. The choice is not cosmetic: coupling reagents differ measurably in reaction rate, in how well they handle sterically hindered residues, and in how much they promote loss of stereochemical integrity at the activated residue.[8]
That last point is worth stating plainly. Activation makes the α-carbon of the incoming residue vulnerable to epimerization — conversion from the L to the D configuration. A peptide with a single inverted stereocentre has the correct molecular formula, the correct mass, and potentially quite different behaviour. Some residues, notably cysteine and histidine, are more prone to this than others. Coupling chemistry is chosen partly to keep that risk low.
What Is Deprotection?
Deprotection is the removal of the temporary protecting group from the N-terminal amine of the resin-bound chain, and it opens every cycle.
The logic is straightforward. After a coupling, the newly added residue sits at the end of the chain with its own α-amine still masked. If it were not masked, that amine would have been free during the coupling step, and the incoming amino acids would have reacted with each other and with the chain indiscriminately. Masking it is what makes the addition stop at exactly one residue. Unmasking it is what permits the next one.
So each cycle alternates between two states: the chain end is either capped and inert, or exposed and ready. Deprotection is the switch.
In Fmoc chemistry this step has a useful side effect. The removed protecting group generates a byproduct that absorbs ultraviolet light, and modern synthesizers monitor that absorbance in real time. Because the amount of byproduct released is proportional to the number of chains that were successfully deprotected, the instrument produces a per-cycle readout of how the synthesis is going. A cycle that releases less than expected is a signal — often the first indication that the chain has begun to aggregate and that later residues will be harder to add. Chemists also use colorimetric tests on small resin samples to check for free amine before proceeding.
This matters because SPPS is otherwise a somewhat blind process. The product stays locked to the resin until the very end, so there is no opportunity to isolate and inspect an intermediate. Per-cycle monitoring is most of the visibility available.
Why Is the Peptide Washed Between Steps?
Washing is the least glamorous step in SPPS and arguably the one that makes it work.
After each deprotection and each coupling, the bead is rinsed repeatedly with solvent. What drains away is everything that is not the peptide: excess amino acid, spent coupling reagents, the cleaved protecting group and its byproducts, reaction additives, and dissolved base or acid.
Removing all of it before the next step serves several purposes at once.
It defines the reaction boundary. Each step should be a clean transition from one chemical state to the next. Residual reagent from a previous step means the next reaction begins in an ill-defined mixture, and its outcome becomes correspondingly less predictable.
It prevents carryover. Leftover activated amino acid from cycle n is still an activated amino acid during cycle n + 1. If it reaches a newly deprotected amine, it inserts an extra residue that does not belong in the sequence — producing an insertion impurity that is closely related to the target and therefore difficult to separate later.
It limits side reactions. Many degradation pathways in peptide chemistry are driven by prolonged exposure to acid or base. Removing those reagents promptly keeps exposure short.
And it exploits the resin’s central advantage. Because purification is filtration, washing is cheap. The method can afford to be thorough in a way that solution-phase chemistry cannot.
Why Peptide Synthesis Produces Impurities
A crude peptide straight off the resin is not a single molecular species. It is a mixture in which the target sequence is — in a well-executed synthesis — the dominant component.
This is not a sign of poor technique. It is arithmetic.
Suppose each coupling in a synthesis proceeds to 99% completion. That is a genuinely good coupling. Now run it 100 times: 0.99100 ≈ 0.366. Roughly 37% of chains carry the complete correct sequence, and 63% carry at least one defect — even though every individual step performed excellently. Push the per-step efficiency to 99.9% and the same 100-cycle synthesis retains about 90% correct chains.
The specific impurities have names, and they are worth distinguishing:
Deletion sequences. A coupling fails on some fraction of chains, but the subsequent deprotection succeeds, and the next residue attaches. The result is a full-length-minus-one peptide missing an internal residue. These are the most troublesome impurities in peptide chemistry: they differ from the target by a single amino acid, so their chromatographic behaviour is often very close to the target’s.
Truncated sequences. A chain stops growing entirely and remains short. Because these differ substantially from the target, they are generally much easier to separate.
Insertion sequences. An extra residue is incorporated, typically from carryover — the failure mode washing is designed to prevent.
Side-reaction products. The best-known example in Fmoc chemistry is aspartimide formation, in which an aspartic acid residue cyclizes with the adjacent backbone amide under basic conditions. The resulting five-membered ring can reopen to give the correct peptide, a rearranged β-linked isomer, or a partially epimerized product — several distinct impurities from one underlying reaction. Aspartimide formation is sequence-dependent and remains an active area of methodological work, with backbone-protecting building blocks among the more effective countermeasures.[9, 10]
Modification and degradation products. Oxidation of methionine or cysteine, incomplete removal of side-chain protecting groups, unwanted alkylation during the final acidic cleavage, and hydrolysis of sensitive residues all contribute.
Non-peptide material. Residual scavengers, counterions from the cleavage and purification steps, and water. These are not impurities in the sequence sense, but they occupy mass in the final vial — a distinction that becomes important at the characterization stage.
None of this means the synthesis was done badly. It means the crude product requires purification, and that purification requires analytical methods capable of resolving species that are, by construction, extremely similar to the target.
Why Longer Peptides Are More Difficult to Synthesize
Two distinct effects compound, and it is worth separating them.
The statistical effect is the arithmetic in Fig. 2. More cycles means more opportunities for incomplete reaction, and yields multiply rather than add. This part is predictable from length alone.
The physical effect is not predictable from length, and it is the harder problem. As a chain grows on the resin, it can begin to fold, and neighbouring chains can associate with one another — typically forming β-sheet-like hydrogen-bonded structures within the swollen polymer network. When that happens, the reactive N-terminus becomes physically buried. Reagents cannot reach it. Coupling efficiency drops sharply, sometimes within a single cycle, and often at a specific point in the sequence rather than gradually.
Sequences prone to this behaviour are known in the field as “difficult sequences”, and the label is descriptive rather than dismissive. Stretches rich in hydrophobic residues such as valine, isoleucine and alanine are common offenders; so are sequences with strong β-sheet propensity. The onset is frequently abrupt: a synthesis proceeds cleanly for fifteen residues, then coupling efficiency collapses.[11, 12]
Individual residues contribute their own difficulties independently of length. Proline’s ring constrains the backbone and can promote diketopiperazine formation early in a synthesis. Sterically hindered residues couple slowly. Arginine, cysteine and histidine each carry characteristic side reactions.
The important qualification: length does not impose a hard ceiling. A range of strategies extends what is achievable — backbone-protecting building blocks and pseudoproline dipeptides that chemically disrupt aggregation, alternative resins with better solvation properties, elevated-temperature and microwave-assisted synthesis, and fragment-based approaches in which shorter segments are made separately and joined. Native chemical ligation, introduced by Dawson, Muir, Clark-Lewis and Kent in 1994, allows two unprotected synthetic segments to be joined chemoselectively into a native peptide bond, opening chemical access to proteins well beyond stepwise reach.[13] More recently, automated flow chemistry has produced polypeptide chains up to 164 residues in a single continuous synthesis — including folded, catalytically active enzymes — over hundreds of consecutive reactions.[14]
The accurate statement is not that long peptides cannot be synthesized. It is that difficulty rises non-linearly with length and depends strongly on sequence, and that longer targets require method development rather than simply more cycles of the standard procedure.
What Happens After Synthesis?
Assembly ends with cleavage: the peptide is released from the resin, and in Fmoc chemistry the side-chain protecting groups are removed in the same operation, using an acidic mixture that also contains scavengers to intercept the reactive fragments those groups generate. Get this step wrong and previously clean material can acquire a new set of modification products.
What remains after the resin is filtered off and the peptide isolated is the crude peptide — the full mixture described above, with the target sequence as the major component.
a mixture separates species establishes what it is
Crude peptide is a legitimate research material for some purposes, but for most work it is an intermediate rather than a product. Two things still have to happen: the target must be separated from everything else, and its identity must be established. These are different operations answering different questions, and conflating them is one of the more common errors in reading peptide documentation.
How Researchers Purify Synthetic Peptides
Purification means physically separating molecular species that are present together — and in peptide chemistry, species that are often extraordinarily similar.
The dominant technique is reversed-phase high-performance liquid chromatography (RP-HPLC). The principle is separation by hydrophobicity. The crude mixture is dissolved and pumped through a column packed with a hydrophobic stationary phase, usually silica particles bearing long alkyl chains. A mobile phase carries the sample through, and its composition is varied over the run — starting mostly aqueous, becoming progressively more organic. Peptides adsorb to the stationary phase and release when the mobile phase becomes hydrophobic enough to compete for them.
Because that release point depends on the molecule’s overall hydrophobic character, species that differ even slightly emerge at different times. Fractions are collected as they elute; those containing the target are pooled, the organic solvent is removed, and the material is typically lyophilized to a solid.
This works remarkably well, but it has limits worth understanding. Deletion sequences missing a single residue — particularly a small or polar one — can elute very close to the target. Epimerized products differ only in stereochemistry and may separate poorly or not at all on a standard achiral column. Purification therefore reduces impurities; it does not necessarily eliminate every class of them, and the classes hardest to remove are precisely the ones most similar to the target.
Purification separates molecular species. It does not identify them.
A synthesis that assembled the wrong sequence, or that epimerized a residue, can still yield a beautifully sharp single peak.
Chromatography reports that a sample contains one dominant component eluting at a particular time under particular conditions. It does not report what that component is. Purity and identity are distinct properties, established by different measurements.
How Do Researchers Know They Made the Right Peptide?
Identity answers: is this molecule the intended sequence?
Purity answers: how much of the sample is that molecule, and what else is present?
A material can score well on one and badly on the other. Both are needed.
Mass spectrometry is the primary identity tool. The peptide is ionized and its mass-to-charge ratio measured with high precision. Because every sequence has a calculable exact mass, a measured mass matching the theoretical value is strong evidence that the correct residues are present in the correct number.
Strong evidence, but not proof — and the reason is instructive. Mass constrains composition without fixing the order, and it does not always fix composition either: glycine twice over has the same elemental formula as a single asparagine. Leucine and isoleucine are isomers with identical mass and cannot be distinguished by mass alone; separating them requires specialized fragmentation techniques.[15] Two peptides containing the same residues in different sequences are exactly isobaric. And epimerization changes no atoms at all, so a peptide with a D-residue where an L-residue belongs has precisely the expected mass.
Tandem mass spectrometry (MS/MS) closes much of this gap. Fragmenting the peptide inside the instrument produces a ladder of ions whose mass differences correspond to individual residues, allowing the sequence to be read directly. This is standard practice in proteomics and increasingly common in the characterization of synthetic material.
Chromatographic purity is usually reported as an area percentage: the target peak’s area divided by the total area of all detected peaks, typically with ultraviolet detection near 214 nm, where the peptide bond itself absorbs.
That definition carries two consequences most readers of a certificate of analysis do not account for.
First, it is relative to what the detector sees. Salts, water, residual solvents and counterions do not absorb meaningfully at that wavelength and therefore do not appear in the calculation at all. A material can be 99% pure by HPLC area and still be substantially less than 99% peptide by mass. In practice, lyophilized synthetic peptides commonly contain a significant fraction of non-peptide mass — bound water and counterions carried over from purification, with the amount depending strongly on how many basic residues the sequence contains.
Second, purity by area and peptide content by mass are different measurements requiring different methods. Peptide content is determined by techniques such as quantitative amino acid analysis, quantitative NMR, or elemental analysis — none of which are chromatography.[16] Serious characterization packages report both, alongside water content, counterion content and residual solvents.
Additional methods fill in the remaining gaps: amino acid analysis confirms composition after hydrolysis; chiral analysis detects epimerization; NMR provides structural detail; specialized assays address disulfide connectivity in cysteine-containing peptides, which mass alone cannot resolve.
The full treatment of these methods belongs in their own articles. The distinction to carry forward is this: a single purity number, unqualified, describes one property measured one way. It is useful information. It is not a complete description of a material.
What Can Go Wrong During Peptide Synthesis
A consolidated view of the failure modes discussed above, roughly in the order they arise.
| Stage | Problem | Consequence |
|---|---|---|
| Loading | Inefficient or uneven attachment of the first residue | Reduced yield; heterogeneous starting population |
| Coupling | Incomplete reaction | Deletion sequences |
| Coupling | Epimerization at the activated residue | Diastereomeric impurity with identical mass |
| Deprotection | Incomplete removal of the temporary group | Truncated or deletion products |
| Deprotection | Base-mediated aspartimide formation | Multiple rearranged and epimerized species |
| Washing | Reagent carryover | Insertion sequences |
| Elongation | On-resin aggregation | Abrupt collapse in coupling efficiency |
| Cleavage | Alkylation by released protecting-group fragments | Covalently modified peptide |
| Cleavage | Incomplete side-chain deprotection | Partially protected peptide |
| Handling | Oxidation of Met or Cys; disulfide scrambling | Modified or misfolded product |
| Purification | Co-elution of closely related impurities | Residual impurity in “purified” material |
Two observations about this table.
Most of these failure modes are anticipated and designed against rather than discovered after the fact. Capping is a good example: after each coupling, remaining unreacted amines can be deliberately and irreversibly blocked. This does not recover the failed chains — but it converts them from deletion sequences, which are hard to separate, into truncated sequences, which are easy. Accepting a small yield loss to make the impurity profile tractable is characteristic of how the field thinks.
And most are sequence-dependent. There is no universal SPPS procedure that is optimal for every target. Method development is a real part of making a peptide, particularly a long or awkward one.
Why Peptide Synthesis Matters for Research Quality
Everything above has a downstream consequence: the material is part of the experiment.
An experiment performed with a peptide measures the behaviour of whatever was actually in the vial. If the sequence is wrong, the result describes a different molecule. If a meaningful fraction of the sample is a deletion product, the effective concentration of the intended peptide is lower than assumed and any dose- or concentration-dependent relationship shifts accordingly. If a fraction is epimerized, the sample contains a stereoisomer that may behave differently. If a substantial share of the mass is water and counterions, a solution prepared by weight is more dilute in peptide than the calculation implies — which is why peptide content, not just purity, appears on rigorous characterization documents.
This connects to reproducibility in a direct way. Two laboratories working from the same published sequence, using material from different sources with different impurity profiles and different peptide content, can obtain different results without either having made a procedural error. The variable was the material. Poorly characterized reagents are a recognized contributor to irreproducibility across the life sciences, and peptides — where similar-looking material can differ in ways that only targeted analysis reveals — are a clear instance of the general problem.
The practical implication is not that researchers should distrust synthetic peptides. It is that characterization data is part of the material, and material without it is harder to interpret. Knowing how a peptide was made, what impurities that process tends to generate, and which analytical methods were applied is what makes a purity figure meaningful rather than decorative.
What We Know — and What Still Has to Be Verified
The chemistry of solid-phase peptide synthesis is exceptionally well established. Sixty years of literature describe the reaction mechanisms, the failure modes, the sequence-dependent difficulties, and the analytical methods used to detect all of the above. This is not a frontier field. It is a mature one, with active methodological development at its edges — greener solvent systems, flow chemistry, improved coupling reagents, aggregation-disrupting building blocks — sitting on a very solid foundation.
What that maturity does not do is transfer automatically to any particular batch of material.
“This peptide can be synthesized” is a statement about chemistry. “This material is the correct peptide, at a defined purity and content” is a statement about a batch.
The first is established by the literature. The second is established only by measurement.
A synthesis route that works reliably says nothing definitive about the vial in front of you; that requires identity confirmation, purity determination, content assay, and — depending on the application — additional testing for stereochemical integrity, disulfide connectivity or residual solvents.
Understanding how peptides are synthesized is ultimately useful for exactly this reason. It tells you which questions to ask about a material, which impurities a given sequence is likely to carry, and why the difference between a chromatogram and a mass spectrum matters. A sequence is a design. A characterized material is a result.
References
- Merrifield RB. Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide. J Am Chem Soc. 1963;85(14):2149–2154. doi:10.1021/ja00897a025
- Wang L, Wang N, Zhang W, et al. Therapeutic peptides: current applications and future directions. Signal Transduct Target Ther. 2022;7:48. doi:10.1038/s41392-022-00904-4
- Gutte B, Merrifield RB. The total synthesis of an enzyme with ribonuclease A activity. J Am Chem Soc. 1969;91(2):501–502. doi:10.1021/ja01030a050
- Isidro-Llobet A, Kenworthy MN, Mukherjee S, et al. Sustainability Challenges in Peptide Synthesis and Purification: From R&D to Production. J Org Chem. 2019;84(8):4615–4628. doi:10.1021/acs.joc.8b03001
- Martin V, Egelund PHG, Johansson H, et al. Replacing DMF in solid-phase peptide synthesis: varying the composition of green binary solvent mixtures as a tool to mitigate common side-reactions. Green Chem. 2021;23(9):3312–3321.
- Isidro-Llobet A, Álvarez M, Albericio F. Amino Acid-Protecting Groups. Chem Rev. 2009;109(6):2455–2504. doi:10.1021/cr800323s
- Carpino LA, Han GY. 9-Fluorenylmethoxycarbonyl function, a new base-sensitive amino-protecting group. J Am Chem Soc. 1970;92(19):5748–5749. doi:10.1021/ja00722a043 — full paper: J Org Chem. 1972;37(22):3404–3409. doi:10.1021/jo00795a005
- El-Faham A, Albericio F. Peptide Coupling Reagents, More than a Letter Soup. Chem Rev. 2011;111(11):6557–6602. doi:10.1021/cr100048w
- Behrendt R, White P, Offer J. Advances in Fmoc solid-phase peptide synthesis. J Pept Sci. 2016;22(1):4–27. doi:10.1002/psc.2836
- Kong X, et al. Aspartimide Formation and Its Prevention in Fmoc Chemistry Solid Phase Peptide Synthesis. ChemBioChem. 2025. doi:10.1002/cbic.202500490
- Coin I, Beyermann M, Bienert M. Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences. Nat Protoc. 2007;2(12):3247–3256. doi:10.1038/nprot.2007.454
- Paradís-Bas M, Tulla-Puche J, Albericio F. The road to the synthesis of “difficult peptides”. Chem Soc Rev. 2016;45(3):631–654. doi:10.1039/c5cs00680e
- Dawson PE, Muir TW, Clark-Lewis I, Kent SBH. Synthesis of proteins by native chemical ligation. Science. 1994;266(5186):776–779. doi:10.1126/science.7973629
- Hartrampf N, Saebi A, Poskus M, et al. Synthesis of proteins by automated flow chemistry. Science. 2020;368(6494):980–987. doi:10.1126/science.abb2491
- Armirotti A, Millo E, Damonte G. How to discriminate between leucine and isoleucine by low energy ESI-TRAP MSn. J Am Soc Mass Spectrom. 2007;18(1):57–63. doi:10.1016/j.jasms.2006.08.011
- Purity assignment for peptide certified reference materials by combining qNMR and LC-MS/MS amino acid analysis results: application to angiotensin II. Anal Bioanal Chem. 2018. doi:10.1007/s00216-018-1272-7
The Dice Journal publishes research-focused content on peptide science. Nothing in this article constitutes medical advice, a therapeutic claim, or guidance on the use of research compounds. Research peptides are laboratory materials intended for research use only and are not approved treatments.

Leave a Reply